Russ Conroy is an Assistant Editor for CancerNetwork. He specializes in medicine and healthcare, focusing on topics such as oncology, hematology, immunotherapy, and medical technology innovations. Russ's work has been featured in prominent publications including AJMC - The American Journal of Managed Care, Dermatology Times, and Oncology Nursing News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Russ Conroy's articles primarily focus on healthcare and pharmaceutical topics, with a significant emphasis on citing data to support the information provided. Given this approach, Russ would likely be interested in pitches that provide access to new or exclusive scientific research findings related to cancer treatment, leukemia, breast cancer, multiple myeloma, and immunotherapy.
Since Russ focuses heavily on citing data and presenting evidence-based information in his articles, he may be particularly responsive to pitches from experts who can provide insights based on the latest clinical trials or research studies within the field of oncology and cancer treatment. Additionally, sources who can offer contextualized expert commentary supported by robust scientific evidence could capture his interest.
While there is no specific geographic focus mentioned for Russ Conroy’s coverage attributes or article titles provided here; it appears that he covers a broad range of international developments in healthcare and pharmaceuticals without being limited to any particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Data from a phase 1/2 trial show durable disease control with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
By: Russ Conroy
Data from a phase 2 trial support further clinical development of AK117 in previously untreated acute myeloid leukemia.
This year's EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.
Data from the SPEARHEAD-1 study support the full FDA approval of afami-cel in this synovial sarcoma population.
By: Russ Conroy
Investigators will share detailed results from the phase 3 SigVie-002 trial assessing sigvotatug vedotin in NSCLC at a future medical meeting.
By: Russ Conroy
Two teams of lung cancer experts face off to determine the optimal first-line treatment regimen in EGFR-mutated metastatic NSCLC.
Data from the phase 3 Precision-T trial support the FDA approval of allogeneic regulatory T-cell–based immunotherapy.
Data from studies including the IRAKLIA trial support the approval of subcutaneous isatuximab plus standard of care in multiple myeloma.
The FDA has assigned a Prescription Drug User Fee Act date of May 13, 2027, for the mezigdomide regimen in relapsed/refractory multiple myeloma.
By: Russ Conroy
Mature overall survival data from the INSIGHT-003 trial compare favorably with historical benchmarks in frontline NSCLC therapy.
